The Winter/Spring 2014 issue of Endeavor (a publication of the Office of Advancement Communications) contains a nice write-up of the TDF . . . what it is and why it’s so very important to our research enterprise. View the article online here.
While you’re there, take a look at the issue dedicated to entrepreneurship and technology transfer.
Eighty faculty and students from the University of Rochester and Cornell converged in Ithaca on Tuesday, 6 May 2014 for the Upstate New York Health Sciences Symposium and Technology Showcase. Attendees heard presentations from Cancer Biology and Neurobiology researchers and later mingled among more than two dozen posters detailing cutting-edge research being conducted at the two universities.
David Williams, one of the world’s leading experts on human vision, has been named a member of the National Academy of Sciences in recognition of his distinguished and continuing achievements in original research. The honor is one of the highest given to a scientist in the United States. Williams was one of 84 scientists selected for 2014.
BIOWORLD TODAY, 21 April 2014
By Marie Powers, Staff Writer
In Greek mythology, Telephus was a son of Heracles who received a wound in battle that would not heal until he returned to the Greek warrior, Achilles, who had inflicted the injury. He was healed by the very spear that had pierced him.
Real life is decidedly more complicated, but the fable is an apt metaphor for Telephus Medical LLC, which is developing a first-in-class humanized monoclonal antibody to prevent Staphylococcus reinfection and osteomyelitis in patients following total hip or knee replacement surgery. The company’s technology is designed to prevent the early events that drive the formation of antibiotic-resistant biofilm infections on implanted medical devices, which today require additional, revision surgery.
Today, University of Rochester President Joel Seligman announced two extraordinary gifts from The Wegman Family Charitable Foundation (WFCF): a $10 million lead gift to the University’s Institute for Data Science and a $7 million gift to support Golisano Children’s Hospital. Together with previous gifts to several programs across the University campuses, today’s announcement brings to $20 million the WFCF’s total contributions to the University’s comprehensive campaign. In recognition of this support for the Institute for Data Science, the Institute’s new landmark building will bear the Wegmans name.
Two UR studies have been taped by Science magazine as among last year’s most important scientific breakthroughs. Naked mole rats – animals that may hold the key to new cancer treatments – were named Vertebrate of the Year, while research that shows that the brain cleans itself while we sleep was named one of the Breakthroughs of the Year.
A new study shows that, when properly manipulated, a population of support cells found in the brain called astrocytes could provide a new and promising approach to treat Parkinson’s disease. These findings, which were made using an animal model of the disease, demonstrate that a single therapy could simultaneously repair the multiple types of neurological damage caused by Parkinson’s, providing an overall benefit that has not been achieved in other approaches.
Palo Alto, CA – March 6, 2014 — iCardiac Technologies, Inc., a leading global provider of cardiac safety assessment services, today announced a partnership transaction with Norwest Venture Partners (NVP), a global, multi-stage investment firm with $3.7 billion in capital under management. iCardiac will leverage the extensive strategic resources NVP has to offer to aggressively pursue significant growth opportunities and serve the rapidly growing needs of its pharmaceutical and medical device clients worldwide. Also as part of today’s announcement, two of NVP’s healthcare investment leaders, Dr. Ryan Harris and Dr. Robert Mittendorff, will join the Company’s board of directors.
The average cost to develop a new drug is about $1.2B and requires 10 to 15 years of development time.* iCardiac’s unique and proprietary technology allows CROs and pharmaceutical sponsors to obtain cardiac safety assessment results with less variance, resulting in smaller sample sizes and less development time. iCardiac is the world’s largest dedicated ECG core laboratory serving the pharmaceutical industry. It currently serves seven of the world’s 10 largest pharmaceutical companies, as well as numerous medium and small biotech, pharmaceutical and medical device clients.
More than 150 entrepreneurs and venture capitalists from throughout New York State gathered at Brighton’s ARTISANworks Tuesday evening to network and to hear some Rochester success stories. Organized by the Upstate Venture Association of New York (UVANY), the event featured an introductory presentation on “The New Rochester” by Richard Glaser and an interactive panel discussion featuring Mike Totterman (iCardiac), David Chauncey (vNomics), Tim Wilson (Arnold Magnetics), and Chris Modesti (Biomaxx). The panel was moderated by Will Hoy (Secrest & Emery). The venue perfectly captured the energy and creativity present in the room. The picture, above, was taken seconds before the UR Ventures banner stand noisily imploded.
Everyone is talking about Dr. Nedergaard’s discovery. We can’t blame them. This has huge potential. But don’t take our word for it . . . .